Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Li, Feng ^a   Ma, Jingqiu ^a   Geng, Shanshan ^a   Wang, Junli ^a   Liu, Jinrong ^a   Zhang, Jie ^a   Sheng, Xiaoyang ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ADULT; ANTHROPOMETRY; APGAR SCORE; ARTICLE; ARTIFICIAL MILK; BIRTH WEIGHT; BODY WEIGHT; BREAST FEEDING; CHILD; CHILD HEALTH CARE; CHINA; CLINICAL FEATURE; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; GESTATIONAL AGE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MALE; NORMAL HUMAN; QUESTIONNAIRE; FECES; INFANT; METABOLISM; NEWBORN;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INFANT; INFANT, NEWBORN; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84924308162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119574     Document Type: Article

References (57)

1. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein; isolation of high quantities of its subunits. Scand J Clin Lab Invest. 1990; 50: 769-774. PMID: 2293338.
2. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990; 336: 763-765. PMID: 1976144.
3. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: A proteomic approach. Electrophoresis. 2000; 21: 665-672. PMID: 10726775.
4. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut. 1993; 34: 1357-1363. PMID: 8244101.
5. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997; 272: 9496-9502. PMID: 9083090.
6. Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurrence in various epithelia. Am J Clin Pathol. 1987; 87: 700-707. PMID: 3296737.
7. Striz I, Trebichavsky I. Calprotectin-a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004; 53: 245-253. PMID: 15209531.
8. Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol. 2001; 70: 130-134. PMID: 11435495.
9. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27: 793-798. PMID: 1411288.
10. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58: 176-180. PMID: 9144308.
11. Bonnin Tomas A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007; 99: 689-693. PMID: 18290691.
12. Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM. 2005; 98: 435-441. PMID: 15879440.
13. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431. PMID: 16474109.
14. Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005; 51: 117-126. PMID: 15819166.
15. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50-54. PMID: 10048733.
16. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1392-1398. doi: 10.1002/ibd.20490 PMID: 18484671.
17. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14: 40-46. PMID: 18022866.
18. Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003; 18: 756-762. PMID: 12795745.
19. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000; 47: 506-513. PMID: 10986210.
20. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32: 171-177. PMID: 11321388.
21. Sykora J, Siala K, Huml M, Varvarovska J, Schwarz J, Pomahacova R. Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis. Acta Paediatr. 2010; 99: 1389-1395. doi: 10.1111/j.1651-2227.2010.01843.x PMID: 20412103.
22. Pang T, Leach ST, Katz T, Jaffe A, Day AS, Ooi CY. Elevated faecal M2-pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood? J Gastroenterol Hepatol. 2014 Nov 5. doi: 10.1111/jgh.12842.
23. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14: 841-845. PMID: 12172403.
24. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr. 2002; 34: 323-324; author reply 324-325. PMID: 11964964.
25. Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert-Jacquin C, Barbot L, et al. High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2004; 89: F353-F355. PMID: 15210674.
26. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002; 91: 45-50. PMID: 11883817.
27. Nissen AC, van Gils CE, Menheere PP, Van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004; 38: 107-108. PMID: 14676607.
28. Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr Metab Immune Disord Drug Targets. 2007; 7: 1-5. PMID: 17346198.
29. Liu JR, Sheng XY, Hu YQ, Yu XY, Westcott J, Miller LV, et al. Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth. BMC Pediatr. 2012; 12: 129. doi: 10.1186/1471-2431-12-129 PMID: 22917269.
30. Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003; 37: 468-472. PMID: 14508218.
31. Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology. 2010; 97: 299-304. doi: 10.1159/000255161 PMID: 19887860.
32. Dorosko SM, Mackenzie T, Connor RI. Fecal calprotectin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeed Med. 2008; 3: 117-119. doi: 10. 1089/bfm.2007.0036 PMID: 18564000.
33. Hestvik E, Tumwine JK, Tylleskar T, Grahnquist L, Ndeezi G, Kaddu-Mulindwa DH, et al. Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: A community-based survey. BMC Pediatr. 2011; 11: 9. doi: 10.1186/1471-2431-11-9 PMID: 21284894.
34. Kukkonen K, Kuitunen M, Haahtela T, Korpela R, Poussa T, Savilahti E. High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. Pediatr Allergy Immunol. 2010; 21: 67-73. doi: 10.1111/j.1399-3038.2009.00907.x PMID: 19566584.
35. Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr. 2007; 44: 407-413. PMID: 17414135.
36. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: An observational study. BMC Gastroenterol. 2012; 12: 5. doi: 10.1186/1471-230X-12-5 PMID: 22233279.
37. Ezri J, Nydegger A. Pediatrics. Fecal calprotectin in children: use and interpretation. Rev Med Suisse. 2011; 7: 69-70. PMID: 21309180.
38. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 14-22. PMID: 11479402.
39. Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010; 51: 542-547. doi: 10.1097/MPG. 0b013e3181e2ad72 PMID: 20818270.
40. Rouge C, Butel MJ, Piloquet H, Ferraris L, Legrand A, Vodovar M, et al. Fecal calprotectin excretion in preterm infants during the neonatal period. PLoS One. 2010; 5: e11083. doi: 10.1371/journal.pone. 0011083 PMID: 20552029.
41. vanElburg RM, Fetter WP, Bunkers CM, Heymans HS. Intestinal permeability in relation to birth weight and gestational and postnatal age. Arch Dis Child Fetal Neonatal Ed. 2003; 88: F52-55. PMID: 12496227.
42. Weaver LT, Laker MF, Nelson R. Intestinal permeability in the newborn. Arch Dis Child. 1984; 59: 236-241. PMID: 6424583.
43. Splichal I, Fagerhol MK, Trebichavsky I, Splichalova A, Schulze J. The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiology. 2005; 209: 681-687. PMID: 15804046.
44. Nash S, Stafford J, Madara JL. Effects of polymorphonuclear leukocyte transmigration on the barrier function of cultured intestinal epithelial monolayers. J Clin Invest. 1987; 80: 1104-1113. PMID: 3116044.
45. Li F, Ma J, Geng S, Wang J, Ren F, Sheng X. Comparison of the different kinds of feeding on the level of fecal calprotectin. Early Hum Dev. 2014; 90: 471-475. doi: 10.1016/j.earlhumdev.2014.06.005 PMID: 25025530.
46. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J Nutr. 2003; 133: 1332-1338. PMID: 12730419.
47. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001; 96: 2683-2687. PMID: 11569695.
48. Caplan A, Walker L, Rasquin A. Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005; 41: 305-316. PMID: 16131985.
49. Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004; 36: 467-470. PMID: 15285526.
50. Ton H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjonsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000; 292: 41-54. PMID: 10686275.
51. Campeotto F, Baldassarre M, Butel MJ, Viallon V, Nganzali F, Soulaines P, et al. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr. 2009; 48: 507-510. doi: 10.1097/MPG.0b013e318186c4a6 PMID: 19322064.
52. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803-813. PMID: 17324124.
53. Aydemir O, Aydemir C, Sarikabadayi YU, Canpolat FE, Erdeve O, Biyikli Z, et al. Fecal calprotectin levels are increased in infants with necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2012.
54. Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg. 2010; 251: 1174-1180. doi: 10.1097/SLA.0b013e3181d778c4 PMID: 20485148.
55. Vaos G, Kostakis ID, Zavras N, Chatzemichael A. The role of calprotectin in pediatric disease. Biomed Res Int. 2013; 2013: 542363. doi: 10.1155/2013/542363 PMID: 24175291.
56. Tamboli CP, Richard F, Colombel JF. Fecal calprotectin in Crohn's disease: new family ties. Gastroenterology. 2003; 124: 1972-1974. PMID: 12806631.
57. Chen CC, Huang JL, Chang CJ, Kong MS. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr. 2012; 55: 541-547. doi: 10.1097/MPG.0b013e318262a718 PMID: 22699836.